{"pageContent": "Background: Treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved rapidly. In particular, five new treatments that extend survival in mCRPC have been approved since 2010, including the chemotherapy cabazitaxel (Jevtana\u00ae), hormonal agents abiraterone (Zytiga\u00ae) and enzalutamide (Xtandi\u00ae), vaccine sipuleucel-T (Provenge\u00ae), and radiopharmaceutical radium-223 (Xofigo\u00ae); all have different indications and toxicity profiles.", "metaData": {"source": "Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines\nhttps://pubmed.ncbi.nlm.nih.gov/20634343/"}}